WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 ...
With more than 40 million men dealing with an enlarged prostate (BPH), chances are either you or someone you know is experiencing the frequent urge to go to the bathroom or slowed urinary flow. For 69 ...
WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced ...
A new medical device offers an alternative to open surgery and drugs for the treatment of benign prostatic hyperplasia. A new medical device offers a less invasive way to treat symptoms caused by an ...
UroLift is a minimally invasive treatment option for benign prostatic hyperplasia (BPH), also called enlarged prostate. Medicare covers the UroLift procedure when a doctor deems it medically necessary ...
Urolift is a minimally invasive procedure to help treat an enlarged prostate, known as benign prostatic hyperplasia (BPH). Medicare will typically cover Urolift procedures when a doctor deems them ...
The UroLift System (Teleflex Inc.) is used to do a prostatic urethral lift, a procedure that relieves lower urinary tract symptoms. It uses implants to pull excess prostatic tissue away from the ...
UroLift is a minimally invasive treatment for Benign Prostatic Hyperplasia, a condition that causes an enlarged prostate in men. The procedure uses tiny implants to lift and hold the enlarged prostate ...
NICE commissioned an external assessment centre (EAC) to review the evidence submitted by the company. This section summarises that review. Full details of all the evidence are in the project ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback